A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-05-18

Study Completion Date

2024-01-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A study to evaluate the safety, pharmacokinetics and anti-tumor activity of RO7300490 as a single agent or in combination with atezolizumab. The study will consist of 3 parts: \[Part 1\] Dose-Escalation of RO7300490 as a single agent; \[Part 2\] Dose-Escalation of RO7300490 in combination with atezolizumab and \[Part 3\] Dose-Expansion of RO7300490 in combination with atezolizumab in selected cancer types.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors

NCT06537310

Cancer-Neoplasms

ACTIVE_NOT_RECRUITING PHASE1

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

NCT06031441

Locally Advanced Solid Tumors Recurrent Solid Tumors Metastatic Solid Tumors

RECRUITING PHASE1

A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.

NCT04642365

Solid Tumors

TERMINATED PHASE1

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

NCT05581004

HCC Locally Advanced or Metastatic Solid Tumors NSCLC +9 more

RECRUITING PHASE1

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors

NCT06488716

Solid Tumour

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Solid Tumors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Part 1: Dose Escalation (RO7300490 Monotherapy)

Participants will receive escalating doses of RO7300490 intravenously (IV) as a single agent for up to 24 months maximum or until progressive disease, unacceptable toxicities, death, or withdrawal of consent.

Group Type EXPERIMENTAL

RO7300490

Intervention Type DRUG

Participants will receive RO7300490, as described in the Arm Descriptions.

Part 2: Dose Escalation (RO7300490/atezolizumab combination therapy)

Participants will receive escalating doses of RO7300490 in combination with a fixed dose of atezolizumab IV (as per label) for up to 24 months maximum or until progressive disease, unacceptable toxicities, death, or withdrawal of consent.

Group Type EXPERIMENTAL

RO7300490

Intervention Type DRUG

Participants will receive RO7300490, as described in the Arm Descriptions.

Atezolizumab

Intervention Type DRUG

Participants will receive Atezolizumab, as described in the Arm Descriptions.

Part 3: Dose Expansion (Disease-specific Expansion(s))

Participants with selected types of advanced and/or metastatic tumors will receive the maximum tolerated dose (MTD) or recommended dose for expansion (RDE) (determined from Parts 1 and 2) of RO7300490 in combination with a fixed dose of atezolizumab IV (as per label). Treatment will be administered for up to 24 months maximum or until progressive disease, unacceptable toxicities, death, or withdrawal of consent.

Group Type EXPERIMENTAL

RO7300490

Intervention Type DRUG

Participants will receive RO7300490, as described in the Arm Descriptions.

Atezolizumab

Intervention Type DRUG

Participants will receive Atezolizumab, as described in the Arm Descriptions.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RO7300490

Participants will receive RO7300490, as described in the Arm Descriptions.

Intervention Type DRUG

Atezolizumab

Participants will receive Atezolizumab, as described in the Arm Descriptions.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Life expectancy of \>= 12 weeks.
* Histologically confirmed diagnosis of locally advanced and/or metastatic solid tumors that are not amenable to standard therapy.
* Radiologically measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
* Agreement to provide protocol-specific biopsy material.
* Adverse Events (AEs) from prior anti-cancer therapy resolved to Grade =\<1.
* Adequate performance status and cardiovascular, hematological, liver, renal and coagulation function.
* For female participants of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse), use contraceptive measures and refrain from donating eggs.
* For male participants: agreement to remain abstinent (refrain from heterosexual intercourse), use contraceptive measures and refrain from donating sperm.

Exclusion Criteria

* Known central nervous system (CNS) primary tumors or metastases, including leptomeningeal metastases, unless protocol-specific conditions are met.
* Active second invasive malignancy within two years prior to screening.
* Significant cardiovascular/cerebrovascular disease within 6 months prior to study treatment start.
* Any other diseases, metabolic dysfunction, physical examination finding or clinical laboratory finding that gives reasonable suspicion of a disease or condition that would contraindicate the use of an investigational drug.
* Prior allogeneic bone marrow transplantation or prior solid organ transplantation.
* Active or history of autoimmune disease.
* Known hypersensitivity to any of the components of RO7300490 formulation or to components of atezolizumab formulation.
* Pregnancy, lactation or breastfeeding.
* Dementia or altered mental status that would prohibit informed consent.
* Major surgery or significant traumatic injury within 28 days prior to the first study drug administration (excluding biopsies) or anticipation of the need for major surgery during study treatment.
* Treatment with radiotherapy, chemotherapy, hormonal therapy, targeted therapy, immunotherapy or investigational drug concurrent or within 28 days or 5 half-lives of the drug (whichever is shorter) before the first study drug administration.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No